ReviewJournal of pregnancy2012
Preeclampsia 2012.
Review in Journal of pregnancy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic Value of microRNA 210 In Preeclampsia
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.
- Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: a meta-analysis.PloS one · 2013Pooled it
- Protein profiling of preeclampsia placental tissues.PloS one · 2014Trial
- An appraisal of the role of asymmetric dimethylarginine on endothelial impairment in preeclampsia comorbid with HIV infection.Frontiers in medicine · 2026Review
- Longitudinal Study of the Vascular Glycocalyx and Urinary Podocyte Markers During Pregnancy.Journal of the American Heart Association · 2025Article
- Article
- Increased Preeclampsia Risk in GDM Pregnancies: The Role of SIRT1 rs12778366 Polymorphism and Telomere Length.International journal of molecular sciences · 2025Article
- Large-scale prospective serum metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia patients.Scientific reports · 2025Article
- Growth arrest and DNA damage-inducible 45: a new player on inflammatory diseases.Frontiers in immunology · 2025Review
- Intrauterine growth-restricted pregnant rats, from placental ischemic dams, display preeclamptic-like symptoms: A new rat model of preeclampsia.Physiological reports · 2024Article
- Association of serum homocysteine with vitamin B12 and folate levels in women with pre-eclampsia in a tertiary health care center in Nepal.BMC women's health · 2024Observational
- The Role of the Aryl Hydrocarbon Receptor in Vascular Factors Related to Preeclampsia in a Smoking Mouse Model.Current issues in molecular biology · 2024Article
- Periodontitis and pre-eclampsia among pregnant women in Rwanda: A case-control study.PloS one · 2024Article
- Physical exercise for a healthy pregnancy: the role of placentokines and exerkines.The journal of physiological sciences : JPS · 2023Review
- Characterization of the lncRNA-mediated ceRNA regulatory networks in preeclampsia by integrated bioinformatics.Scientific reports · 2023Article
- Article
- Preeclampsia Susceptibility Assessment Based on Deep Learning Modeling and Single Nucleotide Polymorphism Analysis.Biomedicines · 2023Article
- Analysis of serum calcium, sodium, potassium, zinc, and iron in patients with pre-eclampsia in Bangladesh: A case-control study.Health science reports · 2023Article
- Effect of Resveratrol on Pregnancy, Prenatal Complications and Pregnancy-Associated Structure Alterations.Antioxidants (Basel, Switzerland) · 2023Review
- Maternal Steroids on Fetal Doppler Indices, in Growth-Restricted Fetuses with Abnormal Umbilical Flow from Pregnancies Complicated with Early-Onset Severe Preeclampsia.Diagnostics (Basel, Switzerland) · 2023Article
- Pathophysiology of Preeclampsia and L-Arginine/L-Citrulline Supplementation as a Potential Strategy to Improve Birth Outcomes.Advances in experimental medicine and biology · 2023Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a common complication of pregnancy associated with high maternal morbidity and mortality and intrauterine fetal growth restriction. There is extensive evidence that the reduction of uteroplacental blood flow in this syndrome results from the toxic combination of hypoxia, imbalance of angiogenic and antiangiogenic factors, inflammation, and deranged immunity. Women treated for preeclampsia also have an increased risk for cardiovascular and renal disease. At present it is unclear if the increased cardiovascular and renal disease risks are due to residual and or progressive effects of endothelial damage from the preeclampsia or from shared risk factors between preeclampsia and cardiac disease. Moreover, it appears that endothelin-1 signaling may play a central role in the hypertension associated with preeclampsia. In this paper, we discuss emerging data on the pathogenesis of preeclampsia and review therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.